FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec

Matthew F. Covington; Clara N. Curiel; Lois Lattimore; Ryan J. Avery; Phillip H. Kuo

doi:10.1097/RLU.0000000000001456

FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec

Matthew F. Covington, Clara N. Curiel, Lois Lattimore, Ryan J. Avery, Phillip H. Kuo^*

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies.

Original language	English (US)
Pages (from-to)	114-115
Number of pages	2
Journal	Clinical nuclear medicine
Volume	42
Issue number	2
DOIs	https://doi.org/10.1097/RLU.0000000000001456
State	Published - Feb 1 2017

Keywords

IMLYGIC
PET
T-VEC
immunotherapy
in-transit metastasis
melanoma
talimogene laherparepvec

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000001456

Cite this

@article{fc449d65603a442f820c75f4f7bc220b,

title = "FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec",

abstract = "61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies.",

keywords = "IMLYGIC, PET, T-VEC, immunotherapy, in-transit metastasis, melanoma, talimogene laherparepvec",

author = "Covington, {Matthew F.} and Curiel, {Clara N.} and Lois Lattimore and Avery, {Ryan J.} and Kuo, {Phillip H.}",

year = "2017",

month = feb,

day = "1",

doi = "10.1097/RLU.0000000000001456",

language = "English (US)",

volume = "42",

pages = "114--115",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec

AU - Covington, Matthew F.

AU - Curiel, Clara N.

AU - Lattimore, Lois

AU - Avery, Ryan J.

AU - Kuo, Phillip H.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - 61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies.

AB - 61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies.

KW - IMLYGIC

KW - PET

KW - T-VEC

KW - immunotherapy

KW - in-transit metastasis

KW - melanoma

KW - talimogene laherparepvec

UR - http://www.scopus.com/inward/record.url?scp=85002245137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002245137&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001456

DO - 10.1097/RLU.0000000000001456

M3 - Article

C2 - 27922859

AN - SCOPUS:85002245137

SN - 0363-9762

VL - 42

SP - 114

EP - 115

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 2

ER -

FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this